Our top pick for
Orphazyme A/S is an other business based in the US. Orphazyme A/S shares (ORPH) are listed on the NASDAQ and all prices are listed in US Dollars. Orphazyme A/S employs 114 staff and has a market cap (total outstanding shares value) of USD$432.8 million.
|52-week range||USD$8.89 - USD$13.98|
|50-day moving average||USD$12.356|
|200-day moving average||USD$10.9292|
|Wall St. target price||USD$21|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||N/A|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$0|
|Return on assets TTM||-54.49%|
|Return on equity TTM||-116.29%|
|Market capitalisation||USD$432.8 million|
TTM: trailing 12 months
There are currently 1,973 Orphazyme A/S shares held short by investors – that's known as Orphazyme A/S's "short interest". This figure is 55% down from 4,389 last month.
There are a few different ways that this level of interest in shorting Orphazyme A/S shares can be evaluated.
Orphazyme A/S's "short interest ratio" (SIR) is the quantity of Orphazyme A/S shares currently shorted divided by the average quantity of Orphazyme A/S shares traded daily (recently around 8220.8333333333). Orphazyme A/S's SIR currently stands at 0.24. In other words for every 100,000 Orphazyme A/S shares traded daily on the market, roughly 240 shares are currently held short.
To gain some more context, you can compare Orphazyme A/S's short interest ratio against those of similar companies.
However Orphazyme A/S's short interest can also be evaluated against the total number of Orphazyme A/S shares, or, against the total number of tradable Orphazyme A/S shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Orphazyme A/S's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Orphazyme A/S shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Orphazyme A/S shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Orphazyme A/S.
Find out more about how you can short Orphazyme A/S stock.
We're not expecting Orphazyme A/S to pay a dividend over the next 12 months.
Over the last 12 months, Orphazyme A/S's shares have ranged in value from as little as $8.89 up to $13.98. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Orphazyme A/S's is 0.8569. This would suggest that Orphazyme A/S's shares are less volatile than average (for this exchange).
To put Orphazyme A/S's beta into context you can compare it against those of similar companies.
Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on developing therapies for diseases caused by misfolding of proteins, including lysosomal storage diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Gaucher disease, sporadic inclusion body myositis, and amyotrophic lateral sclerosis. The company was founded in 2009 and is headquartered in Copenhagen, Denmark.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.